Chronic rejection associated with antiviral therapy for recurrent hepatitis c after living-donor liver transplantation

Transplantation

Volumn 97, Issue 3, 2014, Pages 344-350

  Ueda, Yoshihide ^a   Kaido, Toshimi ^a   Ito, Takashi ^a   Ogawa, Kohei ^a   Yoshizawa, Atsushi ^a   Fujimoto, Yasuhiro ^a   Mori, Akira ^a   Miyagawa Hayashino, Aya ^a   Haga, Hironori ^a   Marusawa, Hiroyuki ^a   Chiba, Tsutomu ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Antiviral therapy; Chronic rejection; Hepatitis C; Liver transplantation; Living donor

Indexed keywords

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FIBROSIS; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERFERONS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894103265     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000435702.61642.0a     Document Type: Article

References (30)

1. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
2. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619.
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28.
5. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allo-graft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56.
7. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV-recipients. Transplantation 2004; 77: 1834.
8. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009; 15: 126.
9. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008; 14: S58.
10. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
11. Fernandez I, Ulloa E, Colina F, et al. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for post-transplant recurrent hepatitis C. Liver Transpl 2009; 15: 948.
12. Stanca CM, Fiel MI, Kontorinis N, et al. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180.
13. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792.
14. Demetris AJ. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 2006; 12: S68.
15. O'Grady J. The immunoreactive patient: rejection and autoimmune disease. Liver Transpl 2011; 17: S29.
16. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868.
17. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067.
18. Dousset B, Conti F, Houssin D, et al. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 1160.
19. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 1084.
20. Stravitz RT, Shiffman ML, Sanyal AJ, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850.
21. Selzner N, Guindi M, Renner EL, et al. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207.
22. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766.
23. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028.
24. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33: 56.
25. Ueda Y, Takada Y, Haga H, et al. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008; 85: 855.
26. Ueda Y, Takada Y, Marusawa H, et al. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010; 90: 661.
27. Ueda Y, Marusawa H, Kaido T, et al. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation. J Viral Hepat 2012; 19: 32.
28. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.
29. Raut V, Mori A, Kaido T, et al. Splenectomy does not offer immu-nological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012; 93: 99.
30. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201.